Summary
In this study, 30 evaluable patients with advanced carcinoma of the breast were treated with cyclophosphamide 600 mg/m2 i.v. followed one day later with mitoxantrone (Novantrone®; dihydroxyanthracenedione) 16 mg/m2 i.v. Drug treatment was repeated every 3–4 weeks, for a maximum of 12 cycles. The overall response rate was 43%; five of 30 patients (16%) attained a complete remission, and eight of 30 (27%) had a partial remission. Median response duration was 12+ months. The greater number of responses was seen in skin and soft tissues. Hematologic toxicity was limiting with 75% of patients experiencing substantial-severe leukopenia. Clinically evident heart failure developed in one patient; in three other patients there was minor-moderate alteration of cardiac function during mitoxantrone-cyclophosphamide therapy. Based on these data, it is believed that this regimen may provide significant long-lasting palliation in patients with advanced breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Haskell CM: Management of metastatic breast cancer. Med Clin N Am 61 (5):967–978, 1977
Hoogstraten B: Adriamycin (NSC-123237) in the treatment of advanced breast cancer: studies by the Southwest Oncology Group. Cancer Chemother Rep 36:329–334, 1975
Schabel FM Jr, Corbett TH, Griswold DP Jr, Laster WR Jr, Trader MW: Therapeutic activity of mitoxantrone and ametantrone against murine tumors. Cancer Treat Rev 10 (Suppl B):13–21, 1983
Stuart-Harris RC, Smith IE: Mitoxantrone: a phase II study in the treatment of patients with advanced breast carcinoma and other solid tumors. Cancer Chemother Pharmacol 8:179–182, 1982
Neidhart JA, Gochonour D, Raach RW, Steinberg JA, Joung D: Mitoxantrone versus doxorubicin in advanced breast cancer: a randomized cross-over trial. Cancer Treat Rev 10 (Suppl B):41–46, 1983
Smith IE, Stuart-Harris RC, Pavlidis N, Bozek T: Mitoxantrone (Novantrone) as single agent and in combination chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rev 10 (Suppl B):37–40, 1983
Hagerber L, Loymds P, Nagel GA: Mitoxantrone HCl, 1, 4-dihydroxy-5, 8-bis((2-((2-hydroxyethyl)amino)ethyl) amino)-9, 10-anthracenedione dihydrochloride. Ein neues zytostaticum. Onkologie 6:322–328, 1980
Von Hoff DD, Pollard E, Kuhn J, Murray E, Coltman CA Jr: Phase I clinical investigation of 1, 4-dihydroxy-5, 8- bis((2-((2-hydroxyethyl)amino)ethyl)amino)-9, 10-anthracenedione dihydrochloride (NSC No. 301739), a new anthracenedione. Cancer Res 40:1516–1518, 1980
Crossley RJ: Clinical safety and tolerance of mitoxantrone. Cancer Treat Rev 10 (Suppl B):29–36, 1983
Jones SE, Durie BG, Salmon SE: Combination chemotherapy with Adriamycin and cyclophosphamide for advanced breast cancer. Cancer 36 (1):90–97, 1975
Weiss RB, Henry JE, DeVita VJ: Multimodal treatment of primary breast cancer. Am J Med 70:844–851, 1981
World Health Organization: WHO handbook for reporting results of cancer treatment. WHO offset publication, no. 48, Geneva, 1979
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Periti, P., Delia Cuna, G.R., Pannuti, F. et al. First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer. Invest New Drugs 3, 167–171 (1985). https://doi.org/10.1007/BF00174165
Issue Date:
DOI: https://doi.org/10.1007/BF00174165